TY - JOUR
T1 - The role of cerebrovascular disease when there is concomitant Alzheimer disease
AU - Vemuri, Prashanthi
AU - Knopman, David S.
N1 - Funding Information:
Dr. Vemuri receives research support from the NIH. Dr. Knopman serves as Deputy Editor for Neurology®; serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study; is an investigator in clinical trials sponsored by TauRX Pharmaceuticals, Lilly Pharmaceuticals and the Alzheimer's Disease Cooperative Study; and receives research support from the NIH.
Funding Information:
We would like to thank Heather Wiste and Scott Przybelski for the Statistical analysis. This work was supported by NIH grants R00 AG37573 , R01 AG11378 , R01 AG041851 , R01 AG03467 , P50 AG16574/P1 , U01 AG06786 ; the Gerald and Henrietta Rauenhorst Foundation grant .
Publisher Copyright:
© 2015 Elsevier B.V.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Cerebrovascular Pathologies (CVP) are the most common co-existent pathologies observed in conjunction with Alzheimer disease. CVP rarely exists in isolation in later life, and CVP most likely plays a supporting role, rather than a sole leading role, in the pathogenesis of dementia. Our goal is to illustrate CVP's role using neuroimaging biomarkers. First, we discuss the frequency of CVP and present data from population-based Mayo Clinic Study of Aging. Here, we used a novel metric for identifying individuals with cerebrovascular imaging abnormalities (that we designate as "V +") and present the frequency of V -/V + in the context of absence and presence of β-amyloid elevation (designated A -/A +). Next, we discuss the contribution of CVP to neurodegeneration and use hippocampal volume loss over time in a subset of participants categorized as A - V -, A - V +, A + V -, A + V + Lastly, we discuss the contribution of CVP to cognitive impairment and conclude with the considerations for design of future studies. This article is part of a Special Issue entitled: Vascular Contributions to Cognitive Impairment and Dementia edited by M. Paul Murphy, Roderick A. Corriveau and Donna M. Wilcock.
AB - Cerebrovascular Pathologies (CVP) are the most common co-existent pathologies observed in conjunction with Alzheimer disease. CVP rarely exists in isolation in later life, and CVP most likely plays a supporting role, rather than a sole leading role, in the pathogenesis of dementia. Our goal is to illustrate CVP's role using neuroimaging biomarkers. First, we discuss the frequency of CVP and present data from population-based Mayo Clinic Study of Aging. Here, we used a novel metric for identifying individuals with cerebrovascular imaging abnormalities (that we designate as "V +") and present the frequency of V -/V + in the context of absence and presence of β-amyloid elevation (designated A -/A +). Next, we discuss the contribution of CVP to neurodegeneration and use hippocampal volume loss over time in a subset of participants categorized as A - V -, A - V +, A + V -, A + V + Lastly, we discuss the contribution of CVP to cognitive impairment and conclude with the considerations for design of future studies. This article is part of a Special Issue entitled: Vascular Contributions to Cognitive Impairment and Dementia edited by M. Paul Murphy, Roderick A. Corriveau and Donna M. Wilcock.
UR - http://www.scopus.com/inward/record.url?scp=84946430861&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946430861&partnerID=8YFLogxK
U2 - 10.1016/j.bbadis.2015.09.013
DO - 10.1016/j.bbadis.2015.09.013
M3 - Article
AN - SCOPUS:84946430861
SN - 0925-4439
VL - 1862
SP - 952
EP - 956
JO - Biochimica et Biophysica Acta - Molecular Basis of Disease
JF - Biochimica et Biophysica Acta - Molecular Basis of Disease
IS - 5
ER -